Sanda, Takaomi

Activating mutations in ALK provide a therapeutic target in neuroblastoma

George, R. E., Sanda, T., Hanna, M., Fröhling, S., II, W. L., Zhang, J., Ahn, Y., Zhou, W., London, W. B., McGrady, P., et al. (2008) · Nature

Neuroblastoma Research and TreatmentsNeurofibromatosis and Schwannoma Cases

Cited by 893

An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element

Mansour, M. R., Abraham, B. J., Anders, L., Berezovskaya, A., Gutierrez, A., Durbin, A. D., Etchin, J., Lawton, L., Sallan, S. E., Silverman, L. B., et al. (2014) · Science

Genomics and Chromatin DynamicsChromatin Remodeling and Cancer

Cited by 801

The Requirement for Cyclin D Function in Tumor Maintenance

Choi, Y. J., Li, X., Hydbring, P., Sanda, T., Stefano, J., Christie, A. L., Signoretti, S., Look, A. T., Kung, A. L., von Boehmer, H., et al. (2012) · Cancer Cell

Cancer-related Molecular PathwaysTelomeres, Telomerase, and Senescence

Cited by 342

Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097

Weisberg, E., Halilovic, E., Cooke, V. G., Nonami, A., Ren, T., Sanda, T., Simkin, I., Yuan, J., Antonakos, B., Barys, L., et al. (2015) · Molecular Cancer Therapeutics

Cancer-related Molecular PathwaysAcute Myeloid Leukemia Research

Cited by 56